Health Catalyst, Inc. (HCAT) intrinsic value & 10-year financials
Health Catalyst, Inc. (HCAT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 19.9% a year to $311.1M, with an average return on invested capital of -5.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.73
- Market cap
- $120.6M
- Revenue (FY2025)
- $311.1M
- Revenue growth (10-yr CAGR)
- 19.9%
- ROIC (10-yr avg)
- -5.6%
- Free cash flow (FY2025)
- -$237.0K
HCAT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $311.1M | -$178.0M | -$2.55 | -$237.0K | -51.7% | -36.7% |
| FY2024 | $306.6M | -$69.5M | -$1.15 | $12.9M | -22.8% | -13.7% |
| FY2023 | $295.9M | -$118.1M | -$2.09 | -$34.3M | -42.9% | -24.0% |
| FY2022 | $276.2M | -$137.4M | -$2.63 | -$37.4M | -50.7% | -25.1% |
| FY2021 | $241.9M | -$153.2M | -$3.23 | -$33.6M | -59.4% | -30.3% |
| FY2020 | $188.8M | -$115.0M | -$2.91 | -$33.9M | -50.9% | -31.2% |
| FY2019 | $154.9M | -$60.1M | -$12.86 | -$34.6M | -35.4% | 75.0% |
| FY2018 | $112.6M | -$62.0M | — | -$42.6M | -53.4% | 15.8% |
| FY2017 | $73.1M | -$47.0M | — | -$39.3M | -62.3% | 19.6% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Health Catalyst, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Health Catalyst, Inc. has historically struggled to out-earn its cost of capital, averaging just -8.8% ROIC.
Health Catalyst, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Health Catalyst, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-84.70 per share.